newsfilter
← Latest News
GlobeNewswire·

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage